For a company founded on insulin a century ago, the most important drug in the world is now a weekly injection for weight loss. But Novo Nordisk is already looking past the syringe, betting that the next frontier for its GLP-1 medicines is not in the clinic but in the medicine cabinet, as a pill. The Danish pharmaceutical giant, which reached nearly 46 million patients with its treatments in 2025, is steering its historic revenue from Ozempic and Wegovy toward a future where oral drugs could capture half the global obesity market [BioSpace, 2026] [Perplexity Sonar Pro Brief]. It is a pivot that demands more than just R&D. It requires a manufacturing footprint to match, a new CFO to manage the financial scale, and a willingness to accept near-term price pain for long-term patient access.
The strategic pivot to pills
The clinical and commercial logic is clear. Injectable GLP-1 drugs like semaglutide have demonstrated profound efficacy for glycemic control and weight loss, but patient preference and adherence often favor oral formulations. Novo Nordisk’s CEO, Maziar Mike Doustdar, has publicly framed the shift as a market-defining move, suggesting weight-loss pills could represent as much as half the global obesity-drug market by 2030 [Perplexity Sonar Pro Brief]. The company is backing this thesis with capital. In September 2026, it agreed to pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for rights to an experimental weight-loss pill, a deal that signals both the strategic priority and the premium for late-stage oral candidates [Perplexity Sonar Pro Brief]. This follows the accelerated rollout of its own Wegovy pill, whose stronger-than-expected sales prompted the company to raise its financial outlook in late 2026 [Reuters, November 2026].
Building the capacity to supply a continent
You cannot serve tens of millions of new patients with pills without the factories to make them. Novo Nordisk’s response has been a multi-billion dollar commitment to U.S. manufacturing, a clear signal that North America is the central battlefield for obesity care. In June 2024, the company announced plans to invest $4.1 billion to build a second fill-and-finish manufacturing facility in Clayton, North Carolina [Novo Nordisk News Details, June 2024]. This came just months after a deal to acquire three fill-finish sites from Novo Holdings A/S [Novo Nordisk News Details, February 2024]. The combined effort is not just about scaling up. It is about securing supply chain resilience and reducing logistical friction for a product category where demand continues to outstrip supply. The buildout also supports a sprawling U.S. workforce; the company employs approximately 10,000 people across more than ten sites in eight states and Washington, D.C. [Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access, 2026].
The leadership and financial engine
Steering a company of this scale through a strategic pivot requires steady financial hands. In November 2026, Novo Nordisk announced a CFO transition, with Karsten Munk Knudsen stepping down after 27 years at the company and eight as CFO [LinkedIn, retrieved 2026]. His successor, Luigi La Corte, joins from Galderma, bringing over 30 years of international financial leadership experience [LinkedIn, retrieved 2026]. The change arrives as the company navigates the complex economics of its blockbuster drugs. CEO Doustdar has described recent U.S. price reductions for Wegovy as “painful” for near-term results but necessary to expand patient access [Reuters, September 2026]. The company had previously warned that pricing agreements for GLP-1 medicines in the U.S. could create a low-single-digit negative impact on 2026 global sales growth [Reuters, November 2025]. These moves highlight a calculated trade-off: sacrificing some margin to cement market leadership and build a durable volume-based business.
The financial muscle to make such bets is formidable. In 2025, the company reported revenue of DKK 309.1 billion (approximately $44 billion), a 10% increase at constant exchange rates, with a net income of DKK 102.4 billion [PharmExec, 2026] [Reuters, Unknown]. This scale funds not only manufacturing and deals but a broad pipeline.
| Metric | Value |
|---|---|
| 2025 Revenue | 309.1 B DKK |
| 2025 Net Income | 102.4 B DKK |
| Global Patient Reach (2025) | 46 M people |
| Total Employees | 55 K people |
Pipeline expansion beyond obesity
While obesity and diabetes dominate the headlines, Novo Nordisk maintains a diversified pipeline, particularly in rare blood disorders. In November 2026, it received European Commission approval for a haemophilia A treatment to prevent or reduce bleeding episodes in adults and children [Reuters, November 2026]. The company is also advancing next-generation obesity candidates, like the investigational CagriSema (a GLP-1 and amylin analogue), which demonstrated about 21% average weight loss in a 2026 trial [Novo Nordisk, 2026]. Not every bet pays off, as evidenced by the June 2024 halt of the ocedurenone CLARION-CKD phase 3 trial for kidney disease after it failed to meet its primary endpoint [Novo Nordisk News Details, June 2024]. This balanced portfolio approach mitigates the risk inherent in any single therapeutic area.
The competitive landscape and risks
The path forward is not without significant pressure. Novo Nordisk’s primary competitor is Eli Lilly, whose drugs Mounjaro and Zepbound directly challenge Ozempic and Wegovy [Perplexity Sonar Pro Brief]. The race for oral GLP-1 dominance will only intensify this rivalry. For a company of Novo Nordisk’s size, several execution risks stand out.
- Manufacturing execution. A $4.1 billion facility build is a multi-year project with inherent risks of delays and cost overruns, which could bottleneck the crucial pill rollout.
- Pricing erosion. Voluntary price cuts in the U.S., while strategic, open the door for further reimbursement pressure and could accelerate margin compression in its largest market [Reuters, September 2026].
- Clinical setbacks. The failure of the ocedurenone trial is a reminder that late-stage pipeline candidates can still stumble, and the high-stakes oral obesity pipeline is not immune [Novo Nordisk News Details, June 2024].
- Market saturation. As more GLP-1 entrants arrive, differentiation becomes harder, potentially turning a breakthrough therapy into a commodity over time.
The company’s answer to these risks is its integrated model: control the supply chain, invest ahead of demand, and compete on both clinical outcomes and access.
The patient at the center
Ultimately, Novo Nordisk’s strategy is aimed at a specific and vast patient population: the hundreds of millions of adults worldwide living with obesity and type 2 diabetes. For these individuals, the standard of care has been a decades-long evolution from basic insulin management to a growing arsenal of incretin-based therapies that address both blood sugar and weight. The current paradigm, however, is still largely built around regular injections, which can be a barrier to initiation and long-term adherence. By pushing toward effective oral formulations, Novo Nordisk is betting on a future where managing these chronic conditions is less burdensome, potentially reaching patients earlier in the disease progression. The success of this bet won’t be measured just in billions of Danish kroner, but in whether it can deliver a more manageable daily reality for the people who need it most.
Sources
- [BioSpace, 2026] ‘Execution, Execution, Execution’: Novo's New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline | https://www.biospace.com/business/execution-execution-execution-novos-new-ceo-doubles-down-on-obesity-diabetes-and-trims-pipeline
- [Perplexity Sonar Pro Brief] Company and product wedge, strategic shift to oral treatments
- [Reuters, November 2026] Novo hikes outlook again as it speeds up Wegovy pill rollout | http://rmb.reuters.com/rmd/rss/item/tag:reuters.com,2026:newsml_KCN3WF0PH?channel=frL012
- [Novo Nordisk News Details, June 2024] Announced plans to invest 4.1 billion US dollars to build a second fill and finishing manufacturing facility in Clayton, North Carolina
- [Novo Nordisk News Details, February 2024] Announced an agreement to acquire three fill-finish sites from Novo Holdings A/S
- [Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access, 2026] Employs approximately 10,000 people in the US
- [LinkedIn, retrieved 2026] Karsten Munk Knudsen was CFO for 8 years and stepped down in 2026 after 27 years at Novo Nordisk
- [LinkedIn, retrieved 2026] Luigi La Corte will join as the new CFO, bringing over 30 years of international financial leadership experience from Galderma
- [Reuters, September 2026] Novo Nordisk sees ‘painful’ US price cuts for Wegovy as investment in the future
- [Reuters, November 2025] Novo Nordisk expects negative low single-digit impact on global sales growth
- [PharmExec, 2026] 2025 sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion
- [Reuters, Unknown] 2025 revenue of DKK 309.064 billion, gross profit of DKK 256.056 billion, and net income of DKK 102.434 billion
- [Reuters, November 2026] Novo’s haemophilia drug gets EU approval | https://www.reuters.com/legal/litigation/novo-nordisks-haemophilia-drug-gets-eu-approval-2026-11-13/
- [Novo Nordisk, 2026] Investigational CagriSema demonstrated ~21% average weight loss in the REDEFINE 9 trial
- [Novo Nordisk News Details, June 2024] In June 2024, the ocedurenone CLARION-CKD phase 3 trial was stopped